13,000 Bottles Of Blood Pressure Medication Recalled Nationwide

Inventia Healthcare Limited, an Indian pharmaceutical company, initiated a voluntary nationwide recall of over 13,000 bottles of its Chlorthalidone-based blood pressure medication earlier this month. The recall, which was later publicized by the U.S. Food and Drug Administration (FDA) in an enforcement report, involves 13,567 bottles distributed across the United States. The FDA has classified this recall as Class II, indicating that the use of the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification is the second-highest designation a recall can receive.

The specific reason cited for the recall is "Failed Dissolution Specifications." According to Good Housekeeping, Chlorthalidone tablets must dissolve within the body to achieve their intended efficacy. If the tablets do not dissolve properly, the blood pressure medication may not function as optimally as expected. This failure in dissolution could potentially lead to reduced effectiveness in managing patients' blood pressure.

The recalled product is specifically identified as Chlorthalidone Tablets, USP, 25 mg, with each bottle containing 100 tablets. The medication is prescription-only (Rx only). The enforcement report from the FDA does not specify the particular pharmacies or other businesses that distributed or received these affected bottles. The recall impacts a significant quantity of medication, underscoring the importance of consumer awareness regarding pharmaceutical recalls. Blood pressure medication is among the most commonly used drug types in the United States, making such recalls a matter of public health concern.

Inventia Healthcare Limited is the manufacturer of the recalled Chlorthalidone tablets. The company, based in India, is responsible for the production and distribution of this specific batch of medication. The FDA's involvement highlights the regulatory oversight in place to ensure the safety and efficacy of pharmaceuticals available to the public. Consumers who may have obtained this specific Chlorthalidone medication are advised to check their supply and consult with their healthcare provider if they have concerns or have been using the affected product. The voluntary nature of the recall suggests a proactive measure by the manufacturer to address a potential quality issue before it leads to widespread adverse health outcomes. The Class II designation implies that while the risk of serious harm is low, there is a definite concern regarding the product's performance and potential impact on patient treatment.